Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9DKC

Structure of URAT1 in complex with TD-3

これはPDB形式変換不可エントリーです。
9DKC の概要
エントリーDOI10.2210/pdb9dkc/pdb
EMDBエントリー46951
分子名称URAT1, 2-({1-[(4-bromonaphthalen-1-yl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl}sulfanyl)-2-methylpropanoic acid (2 entities in total)
機能のキーワードmembrane protein, membrane transporter, transport protein
由来する生物種Homo sapiens
タンパク質・核酸の鎖数1
化学式量合計55836.20
構造登録者
Suo, Y.,Fedor, J.G.,Lee, S.-Y. (登録日: 2024-09-08, 公開日: 2025-06-18)
主引用文献Suo, Y.,Fedor, J.G.,Zhang, H.,Tsolova, K.,Shi, X.,Sharma, K.,Kumari, S.,Borgnia, M.,Zhan, P.,Im, W.,Lee, S.Y.
Molecular basis of the urate transporter URAT1 inhibition by gout drugs.
Nat Commun, 16:5178-5178, 2025
Cited by
PubMed Abstract: Hyperuricemia is a condition when uric acid, a waste product of purine metabolism, accumulates in the blood. Untreated hyperuricemia can lead to crystal formation of monosodium urate in the joints, causing a painful inflammatory disease known as gout. These conditions are associated with many other diseases and affect a significant and increasing proportion of the population. The human urate transporter 1 (URAT1) is responsible for the reabsorption of ~90% of uric acid in the kidneys back into the blood, making it a primary target for treating hyperuricemia and gout. Despite decades of research and development, clinically available URAT1 inhibitors have limitations because the molecular basis of URAT1 inhibition by gout drugs remains unknown. Here we present cryo-electron microscopy structures of URAT1 alone and in complex with three clinically relevant inhibitors: benzbromarone, lesinurad, and the recently developed compound TD-3. Together with functional experiments and molecular dynamics simulations, we reveal that these inhibitors bind selectively to URAT1 in inward-open states. Furthermore, we discover differences in the inhibitor-dependent URAT1 conformations as well as interaction networks, which contribute to drug specificity. Our findings illuminate a general theme for URAT1 inhibition, paving the way for the design of next-generation URAT1 inhibitors in the treatment of gout and hyperuricemia.
PubMed: 40467597
DOI: 10.1038/s41467-025-60480-3
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (2.55 Å)
構造検証レポート
Validation report summary of 9dkc
検証レポート(詳細版)ダウンロードをダウンロード

237735

件を2025-06-18に公開中

PDB statisticsPDBj update infoContact PDBjnumon